Key Points
- Adar1 Capital Management bought 6,400 NextCure shares at an average of $4.95 each, spending $31,680 and increasing its stake by 1.67% to 389,856 shares. The investment firm also purchased shares in two other transactions around the same period.
- NextCure shares were reported down 7.4%, opening at $5.02, with a market capitalization of approximately $18.1 million and a 52-week range of $1.55 to $15.74. The company reported quarterly EPS of negative $1.87, beating the consensus estimate of negative $2.10.
- Institutional investors own approximately 42.65% of NextCure, while analyst sentiment is mixed: the consensus rating is “Hold,” with a target price of $19.00.
NextCure, Inc. (NASDAQ:NXTC - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 3,410 shares of the stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average cost of $5.00 per share, with a total value of $17,050.00. Following the transaction, the insider directly owned 393,266 shares in the company, valued at approximately $1,966,330. This represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The shares were acquired at an average price of $4.95 per share, for a total transaction of $31,680.00.
- On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $38,990.00.
NextCure Stock Performance
NextCure stock opened at $5.02 on Thursday. The stock has a market cap of $18.12 million, a PE ratio of -0.29 and a beta of 1.42. The stock has a 50-day moving average of $3.66 and a two-hundred day moving average of $8.77. NextCure, Inc. has a one year low of $1.55 and a one year high of $15.74.
NextCure (NASDAQ:NXTC - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping analysts' consensus estimates of ($2.10) by $0.23. As a group, sell-side analysts predict that NextCure, Inc. will post -7.89 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have weighed in on NXTC. Wall Street Zen downgraded shares of NextCure from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Zacks Research raised shares of NextCure from a "strong sell" rating to a "hold" rating in a report on Thursday, June 11th. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of NextCure in a research note on Wednesday, July 15th. Finally, Weiss Ratings lowered shares of NextCure from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NextCure currently has an average rating of "Hold" and a consensus target price of $19.00.
Get Our Latest Stock Analysis on NXTC
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in shares of NextCure by 80.0% during the first quarter. Renaissance Technologies LLC now owns 60,534 shares of the company's stock worth $647,000 after purchasing an additional 26,900 shares during the period. Ikarian Capital LLC acquired a new stake in NextCure during the 4th quarter valued at approximately $3,382,000. Squadron Capital Management LLC acquired a new stake in NextCure during the 4th quarter valued at approximately $3,363,000. Millennium Management LLC purchased a new stake in shares of NextCure in the 4th quarter valued at $185,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of NextCure in the 4th quarter valued at $988,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.
NextCure Company Profile
(
Get Free Report)
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure's research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company's pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
